AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
AIM ImmunoTech Inc.
Video analysis: AIM
All videosNo video analysis for this stock yet. Request one from our team.
News: AIM
Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA), the AIM-listed explorer developing the Tulu Kapi gold project in Ethiopia, said all employees affected by last week's security incident have been accounted for, with no further casualties. One employee was killed and Kefi suspended development at the site after the attack on 4 September.
Sintana Energy advances deal to acquire KON-16 in Angola
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has signed definitive agreements for its proposed entry into Angola's Block KON-16, securing an indirect 5% participating interest as the partners work towards a pre-salt exploration well in 2027. The company will pay US$2.5 million for the interest, including US$500,000 already paid to Corcel PLC (AIM:CRCL, FRA:RM4B) and a further US$2 million due on completion.
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition
Ondine Biomedical strikes deal with Mexico's largest private hospital network
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the AIM-listed company behind light-activated antimicrobial therapies, has agreed a partnership with Hospital Ángeles, Mexico's largest private healthcare network, to pilot its Steriwave nasal photodisinfection treatment. The multi-centre pilot follows positive results from Ondine's phase III trial of 5,188 patients across Canadian and US hospitals, which showed a 40% reduction in post-surgical infection rates compared with standard care.
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.
Metals One partner rejects claim that Barbrook mine deal has failed
Lions Bay Resources has rejected a claim by Vantage Goldfields that its proposed acquisition of the Barbrook gold mine in South Africa has failed, describing the statement as false and misleading. The company is owned by Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the AIM-listed mining company, and Lions Bay Capital, which trades on the TSX Venture Exchange.
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference
Video webcast now available here
